CD19 and Pulmonary hemorrhage: To date, regimens of immunosuppression in AAV are recommended as scheduled re-dosing since biomonitoring including CD19+ B cell counts or ANCA titers did not improve clinical outcome (as in this case with AAV presenting as pulmonary hemorrhage despite persistent B cell depletion) [23, 24].